Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea
Botanix has released positive data from its BTX1702 rosacea clinical study.
The Phase 1b/2 randomised, double-blind vehicle-controlled study examined the effects Botanix’s CBD formulation BTX 1702 in adults with moderate to severe papulopustular rosacea over an 8-week treatment period. The study tested two different concentrations of BTX 1702 topical gel – 10% and 20% – alongside a control arm.
Pleasingly, both the 10% and 20% doses showed clinically meaningful results, with the 10% concentration showing statistically significant reduction in inflammatory lesions – an FDA-designated endpoint for the study. A review of the photo evidence from the study also demonstrated visibly reduced redness in target patients.
Both doses were found to be very safe and well tolerated when compared to the control gel.
Botanix medical advisor, Dr Ira Lawrence commented:
“To achieve this level of inflammatory lesion reduction and improvement in both IGA and CEA within 8 weeks is very exciting, particularly with such an excellent safety profile.”
Rosacea affects more than 430 million people worldwide, and the market for treatments is expected to reach US$2.6 billion by 2025.
